Clinical trial
Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial…
NCT00494533 · United Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT00494533 |
|---|---|
| Title | Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension |
| Official title | Treprostinil for Untreated Symptomatic PAH Trial: A 12-Week Multicenter Randomized Double-Blind Placebo-Controlled Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension |
| Acronym | TRUST-1 |
| Lead sponsor | United Therapeutics, Industry |
| Collaborators | Asian Clinical Trials |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Pulmonary Arterial Hypertension |
| Intervention type | Drug |
| Interventions | Remodulin (treprostinil sodium) |
| Enrollment | 45 |
| Start date | Mar 1, 2005 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Jun 29, 2007 |
| Last update posted | Jan 29, 2014 |
| Countries | India |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: